当前位置: 首页 > 期刊 > 《医学信息》 > 2019年第13期
编号:13385382
阿瑞匹坦对于改善Ⅲ~Ⅳ期颅内胶质瘤患者CINV的研究(4)
http://www.100md.com 2019年4月2日 《医学信息》 2019年第13期
     [11]Ando Y,Hayashi T,Ito K,et al.Comparison between 5-day aprepitant and single-dose Fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy[J].Support Care Cancer,2016,24(2):871-878.

    [12]Yahata H,Kobayashi H,Sonoda K,et al.Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen:A multicenter,placebo-controlled,double-blind,randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin[J].Int J Clin Oncol,2016,21(3):491-497.

    [13]Sugimori Y,Ota T,Ujihira T,et al.A phase Ⅱ randomized study to evaluate the efficacy of aprepitant pluspalonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer[J].J Obstet Gynaecol Res,2017,43(9):1454-1459.

    [14]韓刚,杨扬,胡胜利.替莫唑胺通过调控miR-216a/PRKCA抑制胶质瘤细胞U251增殖和侵袭作用的研究[J].现代肿瘤医学,2019,27(10):1713-1717.

    [15]王帅,赵晓丽,朱晗.替莫唑胺治疗复发性原发中枢神经系统淋巴瘤的临床效果[J].南京医科大学学报(自然科学版),2019,39(4):563-565.

    [16]Stupp R,Mason WP,van den Bent MJ,et al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J].N Engl J Med,2005,352(10):987-996.

    收稿日期:2019-4-24;修回日期:2019-5-21

    编辑/肖婷婷, 百拇医药(吴刚 袁华兵)
上一页1 2 3 4